Previous 10 | Next 10 |
Gainers Cumberland Pharmaceuticals (NASDAQ:CPIX) +111%. Adagene (NASDAQ:ADAG) +12%. PLAYSTUDIOS (NASDAQ:MYPS) +7%. Verastem (NASDAQ:VSTM) +6%. Chimerix (NASDAQ:CMRX) +6%. Losers: BELLUS Health (NASDAQ:BLU) -7%. LIZHI (NASDAQ:LIZI) -6%. NRX Pharmaceuticals (NA...
Gainers: Cumberland Pharmaceuticals (NASDAQ:CPIX) +131%. Adagene (NASDAQ:ADAG) +12%. Chimerix (NASDAQ:CMRX) +11%. PLAYSTUDIOS (NASDAQ:MYPS) +8%. Verastem (NASDAQ:VSTM) +6%. Losers: BELLUS Health (NASDAQ:BLU) -7%. LIZHI (NASDAQ:LIZI) -5%. NRX Pharmaceuticals (NASDAQ:NRXP) -5%. G...
Mirati Therapeutics (NASDAQ:MRTX) and Verstatem Oncology (NASDAQ:VSTM) are collaborating to evaluate the former's adagrasib and the latter's VS-6766 in combination for non-small cell lung cancer ("NSCLC"). Adagrasib is a KRAS inhibitor while VS-6766 is a RAF/MEK inhibitor. The ...
Astra Space (NASDAQ:ASTR) +35% after successful commercial orbital launch iSpecimen (NASDAQ:ISPC) +26% selected by U.S. Government and private researchers to supply critical human biospecimens for advanced phase of COVID-19 research PainReform (NASDAQ:PRFX) +19%. Vonage Holding...
Clinical Collaboration to Support the Combination of KRAS G12C Inhibitor Adagrasib with RAF/MEK Inhibitor VS-6766 to Establish Triple Blockade of the RAS Signaling Pathway Mirati Therapeutics, Inc. (Nasdaq:MRTX), a clinical-stage targeted oncology company and Verastem On...
Last week was mixed for the penny stocks and higher-priced ones alike. While there were plenty of trends to follow, some continued gaining steam heading into the middle of November. Sure, you’ve got things like metaverse stocks, short squeeze penny stocks , and your typical low f...
Two new Breakout Stocks for Week 46 with better than 10% short-term upside potential. The ETF/ETN forecast section now goes out in a separate article. Following the Daily Momentum Gauges® the portfolio is up +70.5% YTD despite a record high 24 weeks out 45 weeks this year in nega...
MSCI will be including total 112 companies including Zomedica (NYSE:ZOM), Clovis Oncology (NASDAQ:CLOV), 22nd Century (NASDAQ:XXII), Omeros (NASDAQ:OMER) and Verastem (NASDAQ:VSTM) in its MSCI US Micro Cap Index as a part of Semi-Annual Index Review. MSCI excluded a...
During the semi-annual review, Clovis Oncology (CLVS -1.1%), 22nd Century Group (XXII -1.2%), Verastem (VSTM +8.7%), Omeros (OMER -0.7%), Therapeutics MD (TXMD -3.2%), CEL-SCI (CVM +2.1%), ZIOPHARM Oncology (ZIOP -1.9%), Karyopharm Therapeutics (KPTI +1.1%), Esperion Therapeutics (E...
Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that the Company will present at the Jefferies London Healthcare Conference. The presentation will be made available for on-demand listening be...
News, Short Squeeze, Breakout and More Instantly...
Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the pricing of an underwritten public offering of 13,333,334 shares of its common stock and accompanying warrants to purchase up to 13,333,334 shares of it...
Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of common stock, as well as pre-funded warrants t...
GenFleet’s IND in China was cleared in June 2024; this is the first discovery program from the collaboration Verastem announced in 2023 to advance into human clinical trials Verastem plans to initiate development studies outside of China after evaluating initial dose escalation dat...